×
About 88 results

ALLMedicine Acute Angioedema Center

Research & Reviews  43 results

Significant predictive factors of the severity and outcomes of the first attack of acut...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6844047
BMC Pediatrics; Syue YJ, Li CJ et. al.

Nov 11th, 2019 - The initial episode of angioedema in children can be potential life-threatening due to the lack of prompt identification and treatment. We aimed to analyze the factors predicting the severity and outcomes of the first attack of acute angioedema in...

An 82-year-old man with recurrent angioedema.
https://doi.org/10.2500/aap.2019.40.4242
Allergy and Asthma Proceedings; Schuler CF, Pedersen EA et. al.

Sep 13th, 2019 - Angioedema is a potentially life-threatening swelling condition that can occur either in isolation or in the context of other syndromes, e.g., anaphylaxis. Angioedema is typically asymmetric, lasts for hours to days, is not gravity dependent, and ...

Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
https://clinicaltrials.gov/ct2/show/NCT02586805

Apr 15th, 2019 - This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of DX-2930 in preventing acute angioedema attacks in patients with Type I and Type II HAE.

A Long Term Safety Study of BCX7353 in Hereditary Angioedema
https://clinicaltrials.gov/ct2/show/NCT03472040

Oct 8th, 2018 - This is an open-label study to evaluate the long term safety and effectiveness of oral treatment with BCX7353 in preventing acute angioedema attacks in patients with Type I and Type II HAE.

Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
https://clinicaltrials.gov/ct2/show/NCT03485911

Jul 19th, 2018 - This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of oral BCX7353 in preventing acute angioedema attacks in patients with Type I and Type II HAE.

see more →

Clinicaltrials.gov  43 results

Significant predictive factors of the severity and outcomes of the first attack of acut...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6844047
BMC Pediatrics; Syue YJ, Li CJ et. al.

Nov 11th, 2019 - The initial episode of angioedema in children can be potential life-threatening due to the lack of prompt identification and treatment. We aimed to analyze the factors predicting the severity and outcomes of the first attack of acute angioedema in...

An 82-year-old man with recurrent angioedema.
https://doi.org/10.2500/aap.2019.40.4242
Allergy and Asthma Proceedings; Schuler CF, Pedersen EA et. al.

Sep 13th, 2019 - Angioedema is a potentially life-threatening swelling condition that can occur either in isolation or in the context of other syndromes, e.g., anaphylaxis. Angioedema is typically asymmetric, lasts for hours to days, is not gravity dependent, and ...

Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
https://clinicaltrials.gov/ct2/show/NCT02586805

Apr 15th, 2019 - This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of DX-2930 in preventing acute angioedema attacks in patients with Type I and Type II HAE.

A Long Term Safety Study of BCX7353 in Hereditary Angioedema
https://clinicaltrials.gov/ct2/show/NCT03472040

Oct 8th, 2018 - This is an open-label study to evaluate the long term safety and effectiveness of oral treatment with BCX7353 in preventing acute angioedema attacks in patients with Type I and Type II HAE.

Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
https://clinicaltrials.gov/ct2/show/NCT03485911

Jul 19th, 2018 - This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of oral BCX7353 in preventing acute angioedema attacks in patients with Type I and Type II HAE.

see more →

News  2 results

FDA approves C1-esterase inhibitor for hereditary angioedema
https://www.mdedge.com/pediatrics/article/85840/dermatology/fda-approves-c1-esterase-inhibitor-hereditary-angioedema
Elizabeth Mechcatie

Jul 17th, 2014 - Ruconest, an injectable human recombinant C1-esterase inhibitor, has been approved by the Food and Drug Administration for treating acute angioedema attacks in adults and adolescents with hereditary angioedema. Ruconest is the first recombinant C1.

Study Finds Icatibant Relieves Acute Angioedema
https://www.mdedge.com/familymedicine/article/33684/dermatology/study-finds-icatibant-relieves-acute-angioedema/page/0/1
Family Practice News;

Apr 8th, 2011 - Because many of the adverse events that were most commonly reported are associated with hereditary angioedema, "we could not separate whether this was due to drug effect or due to the attack," Dr. Lumry said.

see more →